Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Abbott Laboratories ABT, -0.78% gained 0.8% in premarket trade Wednesday after the medical-device maker reported second-quarter earnings that topped Wall Street expectations and raised full-year guidance, though the company missed expectations for revenue.

Abbott stock rises after earnings beat, full-year guidance boost

Abbott Laboratories earnings beat second-quarter earnings views. The health care giant raised full-year guidance.

Abbott Earnings Narrowly Top; Health Care Giant Raises Guidance

The FDA approval for MitraClip G4 is expected to enhance Abbott's (ABT) cardiac treatment portfolio.

Abbott MitraClip G4 Gets FDA Nod, Valve Repair Options Expand

Abbott's (ABT) consistent rise on a strong Diabetes Care business performance is seen over the last few quarters.

Will Abbott's (ABT) Q2 Earnings Gain From Overall Growth?

Bio-Rad Laboratories

Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.

ABT or BIO: Which Stock Has Better Potential Right Now?

Illumina

Intuitive Surgical

Johnson & Johnson

These healthcare stocks are breaking down on the charts. Investors should be careful before stepping into these four.

4 Healthcare Stocks That Are Feeling Sick  

Amgen

Eli Lilly

Medtronic

Merck

Novartis

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

The 10 Biggest Healthcare Stocks

Abbott Labs’ (NYSE:ABT) established pharmaceuticals business offers a broad line of branded pharmaceuticals, manufactured worldwide, and marketed and sold outside the U.S. The major products sold through this segment include Creon, Brufen, Biaxin, Influvac, and Duphaston, among others.

How Does Abbott's Established Pharmaceuticals Business Compare With Its Peers?

Abbott has a diversified portfolio of healthcare products that are highly regarded in the market.

Abbott: Long-Term Hold

This healthcare giant is hot. But will Abbott's sizzle fizzle or get even hotter?

Abbott Labs Stock Just Hit an All-Time High: Buy, Sell, or Hold?

Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.

Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers

Provention Bio Inc

These three diabetes stocks have a lot going on this month.

3 Top Diabetes Stocks to Watch in June

iShares Global Healthcare ETF

The patterns forming on the long-term charts suggest that the global health care sector could be poised for a prolonged move higher.

Traders Look to Buy Global Health Care Stocks

New data released by Abbott on the FreeStyle Libre Continuous Glucose Monitor shows it lowers blood sugar levels across the board by nearly a full percentage point in diabetics.

How Abbott's New Continuous Glucose Monitor Can Change The Company

According to the GuruFocus All-In-One Screener, the following health care stocks are popular among gurus.

Five Health Care Stocks Gurus Are Buying

Expect the healthcare giant to hew to the principles that lifted it to where it stands now.

Where Will Abbott Laboratories Be in 10 Years?

We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.

Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges

In the latest trading session, Abbott (ABT) closed at $75.67, marking a -0.05% move from the previous day.

Abbott (ABT) Stock Moves -0.05%: What You Should Know

Autodesk

Cigna

Salesforce

Humana

Intel

Microsoft

NVIDIA

Texas Instruments

To show how business can and must cultivate a Culture of Health, JUST Capital has released new analysis, with support from Robert Wood Johnson Foundation, evaluating how companies perform on core issues of community health.

The Companies Leading On Health For Communities And Families

Abbott (ABT) reported earnings 30 days ago. What's next for the stock?

Why Is Abbott (ABT) Up 3.6% Since Last Earnings Report?

Abbott is a diversified company benefiting from a leadership position in its main markets.

Abbott Laboratories: A Solid Business For An Attractive Valuation

McDonald's

If you're looking for reliable dividend payers, these stocks are for you.

Three Dividend Aristocrats to Buy and Hold Forever.

Becton, Dickinson and Co.

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Quest Diagnostics

Gilead Sciences

While the overall stock market has been very strong year to date, with sectors like technology outperforming, the health care sector, which encompasses everything from pharmaceuticals to biotech to medical devices and more, has been absolutely wretched, lagging the S&P 500 by a huge 9%.

Why 5 Lagging Health Care Giants May Be Incredible Buys Now

Tandem Diabetes Care

Medical device companies like Abbott, Medtronic and Tandem Diabetes are jockeying for a piece of the diabetes treatment market, which could be worth north of $2 trillion by 2030.

A Diabetes Treatment Revolution Could Bolster These Medtech Firms

Chevron

Lincoln Electric Hlds

National Retail Properties

if the analysts are correct, these are five dividend growth stocks that could produce capital gains in addition to their growing dividend payments.

News for Abbott Labs Stock (ABT)